Recombinant Human IFN-alpha-2B Protein, CF

Catalog #: 11013-IF
2 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
11013-IF-010
11013-IF-050

Recombinant Human IFN-alpha-2B Protein Bioactivity.

2 Images

Product Details

Citations (2)

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human IFN-alpha-2B Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129. The ED₅₀ fot this effect is 3.00-60.0 pg/mL.

Source

Human embryonic kidney cell, HEK293-derived human IFN-alpha protein
Cys24-Glu188

Accession #

NP_000596.2

N-terminal Sequence
Analysis

Cys24

Predicted Molecular Mass

19 kDa

SDS-PAGE

18-22 kDa, under reducing conditions.

Product Datasheets

11013-IF

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

11013-IF

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 100 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity

View Larger

Recombinant Human IFN-alpha-2B Protein demonstrates anti-viral activity in HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. The ED₅₀ for this effect is 3.00-60.0 pg/mL

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human IFN-alpha-2B Protein (Catalog # 11013-IF) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 18-22 kDa.

Reconstitution Calculator

Background: IFN-alpha

Interferons (IFN) are a family of cytokines with potent antiviral, antiproliferative and immunomodulatory properties, classified based on their binding specificity to cell surface receptors (1). There are more than a dozen closely related IFN alpha subtypes found in both the human and mouse genome, each sharing about 80% amino acid (aa) sequence homology (2, 3). There are several variants of human IFNA2, IFNA2a, IFNA2b and IFNA2c, which only differ by a few point mutations (4). The extracellular domain (ECD) of mature human IFNA2b shares 59% aa sequence identity with mouse IFNA2. The type I IFNs bind to the interferon alpha receptor (IFNAR), which consists of two subunits: IFNAR1 (alpha -subunit) and IFNAR2 (beta -subunit) (5, 6). While individual IFN alpha subtypes are known to display unique efficacies to viral protection, nothing is known about functions unique to IFNA2 in human physiology. However, IFNA2 has become the representative type I IFN subtype used in basic research and numerous clinical applications (7). Since being first approved for treatment of hairy cell leukemia in 1986, IFNA2b has been approved for the treatment of several malignancies including AIDS-related Kaposi's sarcoma, malignant melanoma and chronic hepatitis B and C (8). More recently, human IFNA2b has been tested as a potential treatment for COVID-19 (9).

References

Pestka S. et al. (1987) Annu Rev Biochem. 56:727.
Matsumiya, T. et al. (2007) J. Immunol. 179:4542.
Schreiber, G. and J. Piehler (2015) Trends Immunol. 36:139.
Lee, N. et al. (1995) J. Interferon Cytokine Res. 15:341.
van Pesch, V. et al. (2004) J. Virol. 78:8219.
James, C.M. et al. (2007) Vaccine. 25(10):1856.
Paul, F. et al. (2015) Gene. 567:132.
Kiladjian, J.J. et al. (2008) Leukemia 22:1990.
Zhou, Q. et al. (2020) Front Immunol. 11:1061.

Long Name

Interferon alpha

Entrez Gene IDs

3440 (Human)

Alternate Names

IFNA; IFNA2; IFNA2b; IFNalpha; IFN-alpha; IFN-alphaA; INFA2; interferon alpha 2; LeIF D

Related Research Areas

Citations for Recombinant Human IFN-alpha-2B Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

2 Citations: Showing 1 - 2
Filter your results:

Filter by:

Data supporting the roles of BAP1, STING, and IFN-beta in ISGF3 activation in ccRCC
Authors: LE Langbein, E Sementino, Z Zhong, W Jiang, L Li, JR Testa, H Yang
Data in Brief, 2022-11-11;45(0):108743.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
MicroRNA Profiles in Monocyte-Derived Macrophages Generated by Interleukin-27 and Human Serum: Identification of a Novel HIV-Inhibiting and Autophagy-Inducing MicroRNA
Authors: T Imamichi, S Goswami, X Hu, S Laverdure, J Yang, J Qiu, Q Chen, BT Sherman, W Chang
International Journal of Molecular Sciences, 2021-01-28;22(3):.
Species: Human
Sample Types: Whole Cells
Applications: Reference Standard